Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/14133
OUTCOME OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN BRAZILIAN CHILDREN: IMMUNOPHENOTYPICAL, HEMATOLOGICAL AND CLINICAL EVALUATION
Author
Affilliation
Funda ção Oswaldo Cruz. Centro dePesquisas Gonçalo Moniz. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Universidade do Estado da Bahia. UNEB. wDepartmento de Ciências da Vida. DCV. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Universidade Federal da Bahia. Faculdade de Farmácia. Salvador, BA, Brasil
Universidade Federal do Amazonas. Faculdade de Farmácia. Amazonas, MA, Brasil
Instituto Nacional de Ciência e Tecnologia do Sangue. INCT. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal do Amazonas. Faculdade de Farmácia. Amazonas, MA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Universidade do Estado da Bahia. UNEB. wDepartmento de Ciências da Vida. DCV. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Universidade Federal da Bahia. Faculdade de Farmácia. Salvador, BA, Brasil
Universidade Federal do Amazonas. Faculdade de Farmácia. Amazonas, MA, Brasil
Instituto Nacional de Ciência e Tecnologia do Sangue. INCT. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal do Amazonas. Faculdade de Farmácia. Amazonas, MA, Brasil
Abstract
Summary: The aim of this study is to investigate the clinical,
hematological, and immunophenotypic characteristics of Brazilian
children with B-cell acute lymphoblastic leukemia (B-ALL) to
identify prognostic biomarkers of the disease. Thirty-three children
newly diagnosed with B-ALL were followed between March 2004
and December 2009. Information about the demographic profile,
diagnosis, immunophenotype, clinical manifestations, and disease
outcome were gathered from the patients’ medical records. Of the
33 patients with B-ALL, 18 were male and 15 female. Eighteen
patients were classified as high risk; 13 as low risk, and 2 as true low
risk. The frequencies of cluster of differentiation (CD)10, CD19,
and CD20 antigens were 69.7%, 81.8%, and 18.2%, respectively.
Six patients (18.2%) had aberrant expression of myeloid antigens.
At diagnosis, patients immunopositive for CD20 had elevated
white blood cell counts (P=0.018) and lower platelet counts
(P=0.017). The 6-year overall survival was 67.5%±3.47%. Our
results demonstrate the distinct immunophenotypic and prognostic
characteristics of patients with B-ALL, which can be related to the
Brazilian racial admixture. Consequently, these results will most
likely aid in the selection of additional prognostic markers and
their use in monitoring the clinical manifestations and treatment
response among B-ALL patients.
Share